7-Methylguanosine lncRNA Signature: Prognostic Validation and Therapy Guidance in Colon Adenocarcinoma

Background: The dysregulation of 7-methylguanosine modification (m7G) and the abnormal expression of long non-coding RNAs (lncRNAs) in colon adenocarcinoma (COAD) require further investigation. Methods: Pearson correlation analysis was conducted to identify m7G-related lncRNAs (m7G-RLs). Cox regression was employed to develop the m7G-RLs prognostic signature (m7G-RLPS). Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was employed to confirm the expression of m7G-RLs in COAD tissues and colon cancer cell lines. The association between m7G-RLPS and immune cells was investigated. The potential utility of m7G-RLPS in forecasting responses to immunotherapy and chemotherapy in colorectal cancer patients was evaluated. Results: This research identified 5,921 m7G-RLs, and 14 lncRNAs were selected to develop the m7G-RLPS. Analysis of DFS revealed that COAD patients in the high-risk group had a markedly reduced survival rate compared to the low-risk group. The m7G-RLPS risk score was independent of sex, age, and TNM stage, making it a more reliable predictor of survival. The GSEA investigated the possible functions of m7G-RLPS involved in COAD development. Additionally, m7G-RLPS is thought to modulate the tumor microenvironment. The m7G-RLPS was shown to have potential utility in predicting the responses of COAD patients to immunotherapy and chemotherapy. Conclusion: The m7G-RLPS was s developed and validated as a reliable tool for predicting the prognosis of COAD patients, serving as a indicator for selecting personalized immunotherapy and chemotherapy options.